Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda approval symbols : INCY save search
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
Incyte Announces U.S. FDA Approval of Opzelura™ (ruxolitinib) Cream, a Topical JAK Inhibitor, for the Treatment of Atopic Dermatitis (AD)
Published: 2021-09-21 (Crawled : 01:00) - biospace.com/
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -0.21%
H: 1.43%
C: 0.41%
treatment fda fda approval dermatitis approval atopic dermatitis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.